Q Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Salt Lake City UT United States (2004)

Organization Overview

First Clinical Trial
2017
NCT02478450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Q Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

human glial restricted progenitor cells (1 trial)

q-cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Myelitis (Phase 2)

Myelitis, Transverse (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2